PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Stopped Recruitment halted prematurely due to competitive landscape for lung cancer therapies

Conditions

• Non-small Cell Lung Cancer

Interventions

• DRUG: PDR001
• DRUG: Cisplatin
• DRUG: Gemcitabine
• DRUG: Pemetrexed
• DRUG: Carboplatin
• DRUG: Paclitaxel
• DRUG: Canakinumab

Sponsor

Novartis Pharmaceuticals